The fibulin-5 protein (FBLN5), encoded by the *FBLN5* gene, is an extracellular matrix (ECM) glycoprotein critical for elastic fiber assembly and tissue integrity. It interacts with integrin receptors and ECM components like tropoelastin, facilitating cell adhesion, migration, and tissue remodeling. FBLN5 antibodies are essential tools for studying its roles in development, wound healing, and diseases.
Research applications include detecting FBLN5 expression via Western blot, immunohistochemistry (IHC), or immunofluorescence (IF) to explore its involvement in pathologies such as age-related macular degeneration, cardiovascular disorders, and cutaneous conditions like cutis laxa. Dysregulated FBLN5 is also linked to cancer progression, where it may act as a tumor suppressor or promoter depending on context, influencing metastasis and angiogenesis.
Commercial FBLN5 antibodies are typically monoclonal or polyclonal, raised against specific epitopes (e.g., human FBLN5 C-terminal regions). Validation ensures specificity in recognizing target isoforms across species. Studies using these antibodies have revealed FBLN5’s dual roles: maintaining elastin homeostasis in healthy tissues versus promoting inflammatory or fibrotic signaling when dysregulated. However, conflicting findings in cancer research highlight context-dependent functions, necessitating further investigation. Overall, FBLN5 antibodies remain vital for elucidating ECM biology and therapeutic targeting.